CTMX Relative Valuation
CTMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTMX is overvalued; if below, it's undervalued.
Historical Valuation
CytomX Therapeutics Inc (CTMX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 13.19. The fair price of CytomX Therapeutics Inc (CTMX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：3.98
Fair
-11.31
PE
1Y
3Y
5Y
Trailing
Forward
-8.12
EV/EBITDA
CytomX Therapeutics Inc. (CTMX) has a current EV/EBITDA of -8.12. The 5-year average EV/EBITDA is -0.57. The thresholds are as follows: Strongly Undervalued below -22.85, Undervalued between -22.85 and -11.71, Fairly Valued between 10.58 and -11.71, Overvalued between 10.58 and 21.72, and Strongly Overvalued above 21.72. The current Forward EV/EBITDA of -8.12 falls within the Historic Trend Line -Fairly Valued range.
-9.33
EV/EBIT
CytomX Therapeutics Inc. (CTMX) has a current EV/EBIT of -9.33. The 5-year average EV/EBIT is -0.14. The thresholds are as follows: Strongly Undervalued below -6.45, Undervalued between -6.45 and -3.30, Fairly Valued between 3.01 and -3.30, Overvalued between 3.01 and 6.16, and Strongly Overvalued above 6.16. The current Forward EV/EBIT of -9.33 falls within the Strongly Undervalued range.
20.07
PS
CytomX Therapeutics Inc. (CTMX) has a current PS of 20.07. The 5-year average PS is 3.48. The thresholds are as follows: Strongly Undervalued below -3.79, Undervalued between -3.79 and -0.15, Fairly Valued between 7.12 and -0.15, Overvalued between 7.12 and 10.75, and Strongly Overvalued above 10.75. The current Forward PS of 20.07 falls within the Strongly Overvalued range.
-11.11
P/OCF
CytomX Therapeutics Inc. (CTMX) has a current P/OCF of -11.11. The 5-year average P/OCF is -4.61. The thresholds are as follows: Strongly Undervalued below -16.50, Undervalued between -16.50 and -10.55, Fairly Valued between 1.33 and -10.55, Overvalued between 1.33 and 7.27, and Strongly Overvalued above 7.27. The current Forward P/OCF of -11.11 falls within the Undervalued range.
-14.69
P/FCF
CytomX Therapeutics Inc. (CTMX) has a current P/FCF of -14.69. The 5-year average P/FCF is -5.83. The thresholds are as follows: Strongly Undervalued below -22.42, Undervalued between -22.42 and -14.13, Fairly Valued between 2.47 and -14.13, Overvalued between 2.47 and 10.76, and Strongly Overvalued above 10.76. The current Forward P/FCF of -14.69 falls within the Undervalued range.
CytomX Therapeutics Inc (CTMX) has a current Price-to-Book (P/B) ratio of 6.15. Compared to its 3-year average P/B ratio of -6.41 , the current P/B ratio is approximately -195.97% higher. Relative to its 5-year average P/B ratio of -32.62, the current P/B ratio is about -118.85% higher. CytomX Therapeutics Inc (CTMX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -69.88%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -64.90% , the current FCF yield is about -100.00% lower.
6.27
P/B
Median3y
-6.41
Median5y
-32.62
-10.68
FCF Yield
Median3y
-69.88
Median5y
-64.90
Competitors Valuation Multiple
The average P/S ratio for CTMX's competitors is , providing a benchmark for relative valuation. CytomX Therapeutics Inc Corp (CTMX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -82.16%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CTMX increased by 296.12% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 0.86 to 17.03.
The secondary factor is the Revenue Growth, contributed -82.16%to the performance.
Overall, the performance of CTMX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is CytomX Therapeutics Inc (CTMX) currently overvalued or undervalued?
What is CytomX Therapeutics Inc (CTMX) fair value?
How does CTMX's valuation metrics compare to the industry average?
What is the current P/B ratio for CytomX Therapeutics Inc (CTMX) as of Dec 05 2025?
What is the current FCF Yield for CytomX Therapeutics Inc (CTMX) as of Dec 05 2025?
What is the current Forward P/E ratio for CytomX Therapeutics Inc (CTMX) as of Dec 05 2025?